Makers Laboratories Limited

Regd. Office : Plot 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai - 400 067 Tel: 022-6111 2800, Fax: 022-6111 2835, E-mail : investors@makerslabs.com Website : www.makerslabs.com CIN : L24230MH1984PLC033389

Unaudited Financial Results for the Quarter and Nine Months Ended 31.12.2016

	Particulars	Quarter Ended			Nine Months Ended		(Rs. Lacs) Year Ended
		31.12.2016	30.09.2016	31.12.2015	31,12,2016	31.12.2015	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Income from Operations						
	(a) Gross Sales / Income from Operations	1,326.45	1,839.21	1,323.40	4,454.25	4,796.74	6,247.78
	(Incl excise duty)						
	(b) Other Operating Income	0.36	1.07	0.81	1.62	12.04	31.85
	Total Income from Operations (gross)	1,326.81	1,840.28	1,324.21	4,455.87	4,808.78	6,279.6
2	Expenses				······		
	(a) Cost of Materials consumed	389.89	438.07	353.07	1,333.07	1,268.60	1,616.66
	(b) Purchase of stock-in-trade	489.68	449.34	170.74	1,472.22	1,405.29	1,779.22
	(c) Changes in inventories of finished goods,	(102.73)	204.86	254.98	(232.21)	143.04	312.39
	work-in-progress and stock-in-trade						
	(d) Excise duty on sales	24.14	30.16	24.69	74.68	112.27	138.63
	(e) Employee benefits expense	150.62	177.65	166.92	501.44	516.64	770.88
	(f) Depreciation and amortisation expense	26.78	27.09	31.64	78.35	93.74	125.01
	(g) Other expenses	235.75	344.95	254.79	871.53	906.50	1,216.33
	Total Expenses	1,214.13	1,672.12	1,256.83	4,099.08	4,446.08	5,959.12
3	Profit / (Loss) from operations before other	112.68	168.16	67.38	356.79	362.70	320.51
	income, finance costs & exceptional items (1-2)						
4	Other Income	12.08	9.63	17.85	32.65	42.61	61.84
5	Profit / (Loss) from ordinary activities before	124.76	177.79	85.23	389.44	405.31	382.35
	finance costs & exceptional items (3+4)						002.00
6	Finance costs	6.96	6.94	8.08	20.75	25.23	32.01
7	Profit / (Loss) from ordinary activities after finance	117.80	170.85	77.15	368.69	380.08	350.34
	cost but before exceptional items (5-6)						
8	Exceptional Items	-	-	-	79.07	-	-
9	Profit / (Loss) from ordinary activities before tax	117.80	170.85	77.15	447.76	380.08	350.34
	(7+8)			,,,,,,	447.70	300.00	350.34
10	Tax expense	25.62	46.44	28.78	122.90	136.17	119.73
11	Net Profit / (Loss) from ordinary activities after tax	92.18	124.41	48.37	324.86	243.91	230.61
	(9-10)						
12	Extraordinary items (net of tax expense)	-	-	-	-	· -	•
13	Net Profit / (Loss) for the period (11-12)	92.18	124.41	48.37	324.86	243.91	230.61
14	Paid-up equity share capital	491.70	491.70	491.70	491.70	491.70	491.70
	(Face value of Rs.10/- each)						
15	Reserves excluding Revaluation Reserve as per	-	-	-	· · · ·		2,142.27
	balance sheet of previous accounting year						2,142.27
16 i	Earnings Per Share (before extraordinary items)						······································
	(of Rs. 10/ each)						
	Basic & Diluted	1.87	2.53	0.98	6.61	4.96	4.69
ii	Earnings Per Share (after extraordinary items) (of		2.33	0.90	0.01	4.30	4.69
	Rs. 10/ each)					· 1	
	Basic & Diluted	1.87	2.53	0.98	6.61	4.96	1.00
		1.07	2.33	0.90	0.01	4.90	4.69

Notes 1. The above unaudited financial results as reviewed by the Audit Committee were approved and taken on record by the Board of Directors in their meeting held on February 3, 2017.

2. The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.

3. Previous year figures have been regrouped, wherever necessary.



nR.A

By Order of the Board akers Laboratories Limited

W

Purnima Jain ple Time Director BIN 00937041

Place : Mumbai Date : February 3, 2017